Information Provided By: 
Fly News Breaks for June 12, 2017
MDCO
Jun 12, 2017 | 07:44 EDT
Leerink analyst Joseph Schwartz lowered his price target for The Medicines Co. to $54 to reflect one-time charges expected in Q2 and lower sales from the company's decision to voluntarily discontinue and withdraw Ionsys. A sale of the asset may have been ideal, but such a move is in-line with management's focus on streamlining the company around inclisiran, Schwartz tells investors in a research note. He keeps an Outperform rating on the shares.
News For MDCO From the Last 2 Days
There are no results for your query MDCO
